<DOC>
	<DOCNO>NCT00089141</DOCNO>
	<brief_summary>RATIONALE : Mycophenolate mofetil add immunosuppressive treatment regimen may effective treat newly diagnose chronic graft-versus-host disease cause stem cell transplantation . It yet know whether immunosuppressive treatment regimen effective without mycophenolate mofetil treat chronic graft-versus-host disease . PURPOSE : This randomized phase III trial study whether addition mycophenolate mofetil improve efficacy immunosuppressive treatment regimens patient newly diagnose chronic graft-versus-host disease .</brief_summary>
	<brief_title>Mycophenolate Mofetil ( MMF ) Treatment Chronic Graft-versus-host Disease ( GVHD )</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy immunosuppressive treatment regimen vs without mycophenolate mofetil patient newly diagnose chronic graft-vs-host disease . - Compare quality life patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled , prospective , multicenter study . Patients stratify accord organ involvement chronic graft-versus-host disease ( GVHD ) ( single organ vs multiple organ ) transplant center . Patients randomize 1 2 treatment arm . All patient receive usual therapy chronic GVHD comprise oral prednisone twice daily oral cyclosporine , oral tacrolimus oral sirolimus twice daily 2 week first evidence improvement symptom chronic GVHD . - Arm I : Patients receive oral mycophenolate mofetil twice daily . - Arm II : Patients receive oral placebo twice daily . In arm administration study drug continue 3 month completion prednisone cyclosporine , tacrolimus sirolimus absence disease progression unacceptable toxicity . Quality life assess baseline every 3 month . Patients follow every 3 month 3-5 year . PROJECTED ACCRUAL : A total 230 patient ( 115 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose chronicgraftversus host disease ( GVHD ) Systemic immunosuppressive treatment indicate AND contraindication treatment mycophenolate mofetil Has undergone prior transplantation type donor , hematopoietic stem cell graft , condition regimen No clinical , laboratory , imagebased evidence know present time enrollment indicate high probability subsequent recurrent progressive disease PATIENT CHARACTERISTICS : Age Any age Performance status Not specify Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Not specify Renal Not specify Pulmonary No known bronchiolitis obliterans manifestation chronic GVHD Immunologic No fungal infection without radiographic evidence improvement continue antifungal therapy No cytomegalovirus ( CMV ) pneumonia without major radiographic evidence improvement No CMV infection without reduction antigenemia viral load continue antiviral therapy No active disseminate varicella zoster viral infection No known hypersensitivity allergy MMF Gastrointestinal Able tolerate oral medication No lactoseintolerant child young swallow capsule No frank blood rectum No melena No known gastrointestinal ulceration Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Female patient must use 2 form contraception 4 week prior , , 6 week completion study treatment Not hospitalized time enrollment No rare , hereditary deficiency hypoxanthineguanine phosphoribosyltransferase ( HGPRT ) PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy Not specify Endocrine therapy Prior treatment prednisone equivalent allow provide dose ≤ 1.0 mg/kg/day time enrollment Concurrent systemic glucocorticoid allow Radiotherapy Not specify Surgery Not specify Other Prior mycophenolate mofetil ( MMF ) prevention treatment acute GVHD allow provide MMF discontinue least 2 week diagnosis chronic GVHD make No prior systemic treatment chronic GVHD No prior treatment chronic GVHD Concurrent antacid allow provide least 2hour interval administration MMF No concurrent systemic immunosuppressive treatment except cyclosporine , tacrolimus sirolimus</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>